Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock

Whilst it may not be a huge deal, we thought it was good to see that the Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Independent Director, Chandra Leo, recently bought US$58k worth of stock, for US$5.84 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The Last 12 Months Of Insider Transactions At Monte Rosa Therapeutics

Notably, that recent purchase by Chandra Leo is the biggest insider purchase of Monte Rosa Therapeutics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of US$5.49. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was Chandra Leo.

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for Monte Rosa Therapeutics

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$2.6m worth of Monte Rosa Therapeutics stock, about 0.7% of the company. We prefer to see high levels of insider ownership.

So What Does This Data Suggest About Monte Rosa Therapeutics Insiders?

The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Monte Rosa Therapeutics stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Monte Rosa Therapeutics. Every company has risks, and we've spotted 4 warning signs for Monte Rosa Therapeutics (of which 1 is significant!) you should know about.

Of course Monte Rosa Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.